Bone Solutions (BSI) closed a private placement memorandum of US $1.5MM, surpassing its goal by achieving a funding round totaling >$1.7MM. BSI also has an additional $1.65MM in committed funding from Next Health, its distribution partner.
This funding precedes slated launch of BSI’s OsteoCrete™ magnesium-based bone void filler. The product is FDA-cleared for long bone and general orthopaedic applications.
Bone Solutions (BSI) closed a private placement memorandum of US $1.5MM, surpassing its goal by achieving a funding round totaling >$1.7MM. BSI also has an additional $1.65MM in committed funding from Next Health, its distribution partner.
This funding precedes slated launch of BSI's OsteoCrete™ magnesium-based...
Bone Solutions (BSI) closed a private placement memorandum of US $1.5MM, surpassing its goal by achieving a funding round totaling >$1.7MM. BSI also has an additional $1.65MM in committed funding from Next Health, its distribution partner.
This funding precedes slated launch of BSI’s OsteoCrete™ magnesium-based bone void filler. The product is FDA-cleared for long bone and general orthopaedic applications.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
